#USA #Class Action #San Francisco #FTC Allegations #Hims & Hers

Hims & Hers Health Class Action Lawsuit: A Wake-Up Call for Investors

Hims & Hers Health, Inc., publicly traded on the NYSE under the ticker symbol HIMS, is currently under fire due to a securities class action lawsuit initiated against the company. This legal action follows a comprehensive complaint filed by the Federal Trade Commission (FTC), accusing Hims of engaging in deceptive business practices that significantly mislead both consumers and investors.

Background on Hims & Hers Health

Founded with the aim of simplifying access to healthcare, Hims & Hers has emerged as a notable player in the telehealth sector. The company's mission revolves around providing transparent healthcare solutions, yet recent developments have cast a shadow over its business ethics. The allegations assert that Hims falsely represented its data protection measures, breaching the trust of its clients and stakeholders.

The FTC's Complaint

The crux of the FTC's complaint rests on serious allegations that Hims shared sensitive consumer health information with third parties, undermining its claims of rigorous privacy protections. It is notable that despite their marketing strategies extolling the virtues of discretion and data protection, the complaint reveals instances where user data was allegedly mishandled.

This includes claims that Hims shared sensitive health data via tracking technologies with major corporations such as Meta Platforms and Snap, which could have profound implications for consumer trust and corporate liability.

Subscription Model Concerns

Moreover, the lawsuit delves into Hims' subscription billing practices. Allegedly, the company enrolled consumers in recurring subscription models without adequately informing them, violating the Restore Online Shoppers’ Confidence Act (ROSCA). Reports indicate consumers were charged for prescription products almost immediately following their intake submissions, a practice not in line with industry standards for patient consultations. This pattern raises significant compliance issues that may lead to further legal scrutiny and regulatory penalties against Hims & Hers.

The Market Reaction

The impact of these allegations was swift and severe, as seen on July 29, 2026, when Hims’ stock plummeted by 14.7%, erasing nearly $970 million in market value within a single day. This dramatic downturn serves as a chilling reminder of how quickly investor confidence can be shattered by allegations of corporate misconduct.

Class Action Details

Investors who suffered considerable losses during the class period that spans from August 4, 2025, to July 29, 2026, are encouraged to take action before the lead plaintiff deadline on November 2, 2026. Legal representatives from Hagens Berman will work to identify affected investors as part of their investigation into Hims’ practices.

Individual investors possessing information relevant to the case or those looking to recover losses should consider reaching out to Hagens Berman. As a firm that has established a reputation for advocating for corporate accountability, they have successfully obtained over $2.9 billion in settlements for their clients in the past.

Conclusion

The ongoing legal developments surrounding Hims & Hers Health highlight the crucial importance of corporate governance, transparency, and ethical practices in maintaining investor trust. As the situation unfolds, it serves as a reminder for investors to remain vigilant and informed regarding their investment choices, particularly in sectors as sensitive as healthcare. With the deadline looming, affected shareholders must act promptly to secure their interests in this unfolding legal drama.